NCT01204203View on ClinicalTrials.gov

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2016

Conditions
Mesothelioma
Interventions
DRUG

Zometa

Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Alabama at Birmingham

OTHER